|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
随机、双盲、安慰剂对照、多中心临床试验评价艾替沙敏胶囊治疗腹泻型IBS的临床疗效和安全性
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the clinical efficacy and safety of atixamin capsules in the treatment of diarrhea-predominant IBS
在以往I、II、III期临床试验的基础上,进一步评价艾替沙敏胶囊治疗腹泻型肠易激综合征的有效性和安全性。
[Translation] Based on previous phase I, II, and III clinical trials, the efficacy and safety of atixamin capsules in the treatment of diarrhea-predominant irritable bowel syndrome were further evaluated.
[Translation] A multicenter randomized withdrawal clinical trial of eticholamine in the treatment of IBS-D
在以往Ⅰ、Ⅱ、Ⅲ期临床试验的基础上,进一步评价艾替沙敏胶囊治疗腹泻型肠易激综合征的安全性和有效性,同时探讨本品的疗效与肠道微生态的关系。
[Translation] On the basis of previous phase I, II and III clinical trials, this study further evaluated the safety and efficacy of atixamin capsules in the treatment of diarrhea-predominant irritable bowel syndrome, and explored the relationship between the efficacy of this product and intestinal microecology.
100 Clinical Results associated with Suzhou Bawei Medicine Development & Research Institute Co., Ltd.
0 Patents (Medical) associated with Suzhou Bawei Medicine Development & Research Institute Co., Ltd.
100 Deals associated with Suzhou Bawei Medicine Development & Research Institute Co., Ltd.
100 Translational Medicine associated with Suzhou Bawei Medicine Development & Research Institute Co., Ltd.